文献速递类风湿关节炎

在出现新发肌肉骨骼症状且第二代抗环瓜氨酸肽抗体阴性的个体中检测第三代抗环瓜氨酸肽抗体的效用

Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test.
PubMed 文献 · RMD Open · 2024-04-10

研究纳入469例第二代抗环瓜氨酸肽抗体(anti-CCP2)阴性且新发肌肉骨骼症状的个体,基线检测第三代抗体(anti-CCP3)并随访12个月问卷,由风湿科医生确认是否进展为炎症性关节炎(IA)。仅16/469(3.4%)anti-CCP3阳性,其中4例进展为IA;作者结论认为anti-CCP3检测可能改善此类人群IA发展的预测。

要点

  • 469例anti-CCP2阴性新发肌肉骨骼症状者中仅16例(3.4%)anti-CCP3阳性,其中4例进展为IA。
  • anti-CCP3阳性与自我报告的进展(p<0.01)及IA(p=0.03)相关,但与RA无显著关联。
  • 采用优化低阈值(≥5单位)时,多变量分析中该阈值与RA诊断相关(p=0.02)。

核心结论

  • 作者认为,anti-CCP3检测可能改善anti-CCP2阴性且新发肌肉骨骼症状个体中IA发展的预测。

研究设计与样本

  • 469例anti-CCP2阴性个体接受基线anti-CCP3检测(QUANTA Lite CCP3;Inova Diagnostics)并完成入组后12个月问卷,由风湿科医生确认或排除IA诊断,并进行单变量和多变量分析。

主要发现

  • 仅16/469(3.4%)anti-CCP2阴性个体anti-CCP3阳性,这16例中4例进展为IA。
  • 61/469(13.0%)anti-CCP2阴性个体自我报告发生IA,其中43/61(70.5%)经确认进展,43例中30/43(69.8%)诊断为IA、13/43(30.2%)诊断为类风湿关节炎(RA)。
  • 定性单变量分析中,anti-CCP3阳性与自我报告的进展(p<0.01)及IA(p=0.03)相关,但与RA无显著关联。
  • 在全部三个类别中,进展者与非进展者间anti-CCP3水平差异显著(p<0.01)。
  • 采用厂家阈值时,进展的OR从2.4(95%CI 0.5至18.6;RA)到7.5(95%CI 2.3至24.0;自我报告的进展);优化阈值下较低值(≥5单位)显著提高全部三个类别中进展的OR。

关键数值与推荐

  • anti-CCP3阳性定义为采用QUANTA Lite CCP3(Inova Diagnostics)检测,厂家阈值下判为阳性。
  • 优化阈值下anti-CCP3≥5单位与RA诊断相关(p=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the role of third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in predicting progression to inflammatory arthritis (IA) in individuals with new musculoskeletal (MSK) symptoms and a negative second-generation anti-CCP antibody test (anti-CCP2-). METHODS: 469 anti-CCP2- individuals underwent baseline anti-CCP3 testing (QUANTA Lite CCP3; Inova Diagnostics) and received a post enrolment 12-month questionnaire. A rheumatologist confirmed or excluded diagnosis of IA. Univariable/multivariable analyses were performed to assess the value of anti-CCP3 in predicting IA development in these anti-CCP2- individuals. RESULTS: Only 16/469 (3.4%) anti-CCP2- individuals had a positive anti-CCP3 test. Of these 16 individuals, 4 developed IA. In addition, 61/469 (13.0%) anti-CCP2- individuals self-reported, to have developed, IA. Progression was confirmed in 43/61 of them (70.5%); of whom 30/43 (69.8%) and 13/43 (30.2%) were given a diagnosis of IA and rheumatoid arthritis (RA), respectively. In qualitative univariable analysis, anti-CCP3 positivity was associated with self-reported progression (p<0.01) and IA (p=0.03), but not with RA. Anti-CCP3 levels differed significantly between progressors and non-progressors (p<0.01) for all three categories. At the manufacturer's cut-off, OR for progression ranged from 2.4 (95% CI 0.5 to 18.6; RA) to 7.5 (95% CI 2.3 to 24.0; self-reported progression). Interestingly, when cut-offs for anti-CCP3 were optimised, lower values (≥5 units) significantly increased the OR for progression in all three categories. In multivariable analysis, anti-CCP3 positivity at the manufacturer's cut-off did not remain associated with IA progression, while this lower cut-off value (≥5 units) was associated with diagnosis of RA (p=0.02). CONCLUSIONS: Anti-CCP3 testing could improve the prediction of IA development in anti-CCP2- individuals with new MSK symptoms.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Di Matteo A, Mankia K, Garcia-Montoya L, et al. Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test. RMD Open. 2024. PMID: 38599655. doi:10.1136/rmdopen-2023-003927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。